{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:39:46Z","timestamp":1771562386295,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3111,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1038\/mt.2008.18","type":"journal-article","created":{"date-parts":[[2008,2,19]],"date-time":"2008-02-19T09:40:04Z","timestamp":1203414004000},"page":"682-690","source":"Crossref","is-referenced-by-count":39,"title":["Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor\u2013induced Behavioral Deficits"],"prefix":"10.1016","volume":"16","author":[{"given":"Gwendalyn D","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt M","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianela","family":"Candolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene M","family":"Manalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKM Ghulam","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N","family":"Pechnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro R","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2008.18_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-007-9400-9","article-title":"Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression","volume":"85","author":"Candolfi","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1038\/mt.2008.18_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0163-7258(03)00014-7","article-title":"Current and future strategies for the treatment of malignant brain tumors","volume":"98","author":"Castro","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1038\/mt.2008.18_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2174\/156802605774370856","article-title":"Combining cytotoxic and immune-mediated gene therapy to treat brain tumors","volume":"5","author":"Curtin","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1038\/mt.2008.18_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/156652305774964631","article-title":"Gene therapy and targeted toxins for glioma","volume":"5","author":"King","year":"2005","journal-title":"Curr Gene Ther"},{"key":"10.1038\/mt.2008.18_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/B:NEON.0000003588.18644.9c","article-title":"Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I\/II multi-institutional trial","volume":"65","author":"Prados","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1038\/mt.2008.18_bib6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","article-title":"Gene therapy for malignant glioma: current clinical status","volume":"12","author":"Pulkkanen","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib7","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","article-title":"A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting","volume":"10","author":"Chiocca","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2004.08.002","article-title":"AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study","volume":"10","author":"Immonen","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2008.18_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.18_bib11","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1089\/hum.1998.9.17-2595","article-title":"A phase I\/II study of herpes simplex virus type 1 thymidine kinase \u201csuicide\u201d gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma","volume":"9","author":"Klatzmann","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.18_bib12","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1089\/104303400750035726","article-title":"Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses","volume":"11","author":"Sandmair","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.18_bib13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.cgt.7700651","article-title":"Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector","volume":"10","author":"Rubinchik","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2008.18_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.cgt.7701065","article-title":"Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors","volume":"14","author":"Tsurushima","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2008.18_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3171\/jns.2007.106.4.646","article-title":"Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells","volume":"106","author":"Uzzaman","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1038\/mt.2008.18_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.gt.3300805","article-title":"Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans","volume":"6","author":"Palu","year":"1999","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.18_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02700029","article-title":"Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene\u2013a phase I\/II clinical protocol","volume":"64","author":"Ren","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1038\/mt.2008.18_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1349-7006.2002.tb01262.x","article-title":"Antitumor effect of an adeno-associated virus vector containing the human interferon-\u03b2 gene on experimental intracranial human glioma","volume":"93","author":"Yoshida","year":"2002","journal-title":"Jpn J Cancer Res"},{"key":"10.1038\/mt.2008.18_bib19","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.18_bib20","author":"ArkTherapeutics"},{"key":"10.1038\/mt.2008.18_bib21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/15207","article-title":"Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials","volume":"5","author":"Dewey","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2008.18_bib22","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-04-3434","article-title":"Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model","volume":"65","author":"Ali","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2008.18_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ymthe.2004.08.025","article-title":"Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression","volume":"10","author":"Ali","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib24","article-title":"Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model","author":"King","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1038\/mt.2008.18_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"key":"10.1038\/mt.2008.18_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymthe.2004.05.021","article-title":"Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration","volume":"10","author":"Hurtado-Lorenzo","year":"2004","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"10.1038\/mt.2008.18_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.euroneuro.2006.04.009","article-title":"Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease","volume":"17","author":"Torres","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1038\/mt.2008.18_bib29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ymthe.2006.06.009","article-title":"Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease","volume":"14","author":"Vercammen","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib30","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.176.6.3566","article-title":"Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain","volume":"176","author":"Curtin","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/mt.2008.18_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1471-4906(01)02063-4","article-title":"Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective","volume":"23","author":"Lowenstein","year":"2002","journal-title":"Trends Immunol"},{"key":"10.1038\/mt.2008.18_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6","article-title":"Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations","volume":"405","author":"McMenamin","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1038\/mt.2008.18_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1750-3639.2003.tb00003.x","article-title":"Inflammation in the central nervous system: the role for dendritic cells","volume":"13","author":"Pashenkov","year":"2003","journal-title":"Brain Pathol"},{"key":"10.1038\/mt.2008.18_bib34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1006\/mthe.2001.0479","article-title":"Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS","volume":"4","author":"Zermansky","year":"2001","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/S1740925X07000579","article-title":"Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells may be related to the specific formation of immunological synapses between T cells and virus-infected brain cells","volume":"2","author":"Barcia","year":"2007","journal-title":"Neuron Glia Biol"},{"key":"10.1038\/mt.2008.18_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/mthe.2000.0224","article-title":"Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain","volume":"3","author":"Thomas","year":"2001","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2008.18_bib37","first-page":"239","article-title":"Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus","volume":"1","author":"Cotten","year":"1994","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.18_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0166-0934(95)01973-1","article-title":"Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks","volume":"56","author":"Dion","year":"1996","journal-title":"J Virol Methods"},{"key":"10.1038\/mt.2008.18_bib39","series-title":"Current Protocols in Neuroscience","first-page":"4.23.21","article-title":"Gene transfer into neural cells in vivo using adenoviral vectors","author":"Southgate","year":"2000"},{"key":"10.1038\/mt.2008.18_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/exnr.2002.8021","article-title":"Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine","volume":"178","author":"Tillerson","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2008.18_bib41","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1523\/JNEUROSCI.22-15-06790.2002","article-title":"Forced nonuse in unilateral parkinsonian rats exacerbates injury","volume":"22","author":"Tillerson","year":"2002","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2008.18_bib42","series-title":"Current Protocols in Neuroscience","first-page":"4.23.1","article-title":"Gene transfer into rat brain using adenoviral vectors","author":"Thomas","year":"2015"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616314496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616314496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T04:02:03Z","timestamp":1557288123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616314496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1525001616314496"],"URL":"https:\/\/doi.org\/10.1038\/mt.2008.18","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}